Skip to main content
Premium Trial:

Request an Annual Quote

Additional PPOs to Cover Signal Genetics Multiple Myeloma Test

NEW YORK (GenomeWeb) – Signal Genetics today announced agreements with three preferred provider organizations to cover the firm's multiple myeloma prognostic molecular diagnostic test.

The deals are with Stratose, USA Managed Care Organization, and Evolutions Health Systems, and provide covered access to Signal Genetics' MyPRS test to more than 21 million patients in the US. In total, more than 93 million patients in the US are covered for the test by payors, the Carlsbad, California-based company said.

MyPRS is microarray-based prognostic test for multiple myeloma and stratifies patients into molecular subtypes and into high- and low-risk categories using gene expression profiling. Signal Genetics reached an agreement during the summer with America's Choice Provider Network to provide coverage of the assay.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.